603014 威高血净
已收盘 10-13 15:00:00
资讯
新帖
简况
股市必读：威高血净新发布《山东威高血液净化制品股份有限公司关于使用暂时闲置募集资金进行现金管理到期赎回的公告》
证券之星 · 10-12 03:44
股市必读：威高血净新发布《山东威高血液净化制品股份有限公司关于使用暂时闲置募集资金进行现金管理到期赎回的公告》
【读财报】9月上市公司定增动态：募资总额超417亿元 威高血净、华虹公司募资额居前
新华财经 · 10-09
【读财报】9月上市公司定增动态：募资总额超417亿元 威高血净、华虹公司募资额居前
威高血净：关于使用暂时闲置募集资金进行现金管理到期赎回的公告
同花顺 · 10-08
威高血净：关于使用暂时闲置募集资金进行现金管理到期赎回的公告
股市必读：威高血净新发布《山东威高血液净化制品股份有限公司发行股份购买资产暨关联交易实施情况暨新增股份上市公告书（摘要）》
证券之星 · 09-28
股市必读：威高血净新发布《山东威高血液净化制品股份有限公司发行股份购买资产暨关联交易实施情况暨新增股份上市公告书（摘要）》
威高血净（603014）披露发行股份购买资产暨关联交易实施情况暨新增股份上市公告书（摘要），9月24日股价下跌1.36%
证券之星 · 09-24
威高血净（603014）披露发行股份购买资产暨关联交易实施情况暨新增股份上市公告书（摘要），9月24日股价下跌1.36%
威高血净最新公告：控股股东变更为威高股份
证券之星 · 09-24
威高血净最新公告：控股股东变更为威高股份
股市必读：威高血净（603014）9月22日董秘有最新回复
证券之星 · 09-23
股市必读：威高血净（603014）9月22日董秘有最新回复
股市必读：威高血净（603014）9月17日董秘有最新回复
证券之星 · 09-18
股市必读：威高血净（603014）9月17日董秘有最新回复
威高血净：公司密切关注AI等新技术在研发、生产领域的应用趋势
证券之星 · 09-17
威高血净：公司密切关注AI等新技术在研发、生产领域的应用趋势
每周股票复盘：威高血净（603014）并购威高普瑞获证监会通过
证券之星 · 09-13
每周股票复盘：威高血净（603014）并购威高普瑞获证监会通过
威高血净：9月7日召开业绩说明会，投资者参与
证券之星 · 09-07
威高血净：9月7日召开业绩说明会，投资者参与
每周股票复盘：威高血净（603014）获准发行股份收购威高普瑞
证券之星 · 09-06
每周股票复盘：威高血净（603014）获准发行股份收购威高普瑞
股市必读：威高血净新发布《山东威高血液净化制品股份有限公司关于发行股份购买资产暨关联交易事项获得中国证券监督管理委员会同意注册的批复的公告》
证券之星 · 09-02
股市必读：威高血净新发布《山东威高血液净化制品股份有限公司关于发行股份购买资产暨关联交易事项获得中国证券监督管理委员会同意注册的批复的公告》
威高血净（603014）披露使用暂时闲置募集资金进行现金管理到期赎回的公告，9月1日股价上涨0.67%
证券之星 · 09-01
威高血净（603014）披露使用暂时闲置募集资金进行现金管理到期赎回的公告，9月1日股价上涨0.67%
股市必读：威高血净新发布《山东威高血液净化制品股份有限公司关于发行股份购买资产暨关联交易事项获得中国证券监督管理委员会同意注册的批复的公告》
证券之星 · 09-01
股市必读：威高血净新发布《山东威高血液净化制品股份有限公司关于发行股份购买资产暨关联交易事项获得中国证券监督管理委员会同意注册的批复的公告》
威高血净（603014）披露发行股份购买资产获证监会注册批复，8月31日股价下跌1.56%
证券之星 · 08-31
威高血净（603014）披露发行股份购买资产获证监会注册批复，8月31日股价下跌1.56%
每周股票复盘：威高血净（603014）Q2净利增3.31%
证券之星 · 08-30
每周股票复盘：威高血净（603014）Q2净利增3.31%
股市必读：威高血净新发布《山东威高血液净化制品股份有限公司2026年半年度报告摘要》
证券之星 · 08-27
股市必读：威高血净新发布《山东威高血液净化制品股份有限公司2026年半年度报告摘要》
图解威高血净中报：第二季度单季净利润同比增长3.31%
证券之星 · 08-25
图解威高血净中报：第二季度单季净利润同比增长3.31%
股市必读：威高血净（603014）8月24日董秘有最新回复
证券之星 · 08-25
股市必读：威高血净（603014）8月24日董秘有最新回复
加载更多
公司概况
公司名称：
山东威高血液净化制品股份有限公司
所属行业：
专用设备制造业
上市日期：
2025-05-19
主营业务：
山东威高血液净化制品股份有限公司的主营业务是血液净化医用制品的研发、生产和销售。公司的主要产品是血液透析器、血液透析管路、血液透析机以及腹膜透析液。报告期内，公司收到中华人民共和国工业和信息化部下发的《制造业单项冠军企业证书》。
发行价格：
26.50
{"stockData":{"symbol":"603014","market":"SH","secType":"STK","nameCN":"威高血净","latestPrice":29.31,"timestamp":1791874800000,"preClose":29.93,"halted":0,"volume":1568263,"delay":0,"changeRate":-0.0207,"floatShares":101000000,"shares":695000000,"eps":0.7079,"marketStatus":"已收盘","change":-0.62,"latestTime":"10-13 15:00:00","open":29.82,"high":29.88,"low":29.18,"amount":46078500,"amplitude":0.0234,"askPrice":29.32,"askSize":1,"bidPrice":29.31,"bidSize":1,"shortable":0,"etf":0,"ttmEps":0.7079,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791941400000},"marketStatusCode":5,"adr":0,"adjPreClose":29.93,"symbolType":"stock","openAndCloseTimeList":[[1791855000000,1791862200000],[1791867600000,1791874800000]],"highLimit":32.92,"lowLimit":26.94,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":694798783,"isCdr":false,"pbRate":2.82,"roa":"--","peRate":41.404153,"roe":"3.2%","epsLYR":1.22,"committee":0.487603,"marketValue":20365000000,"turnoverRate":0.0155,"status":1,"floatMarketCap":2975000000},"requestUrl":"/m/hq/s/603014","defaultTab":"news","newsList":[{"id":"2674846914","title":"股市必读：威高血净新发布《山东威高血液净化制品股份有限公司关于使用暂时闲置募集资金进行现金管理到期赎回的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674846914","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674846914?lang=zh_cn&edition=full","pubTime":"2026-10-12 03:44","pubTimestamp":1791747854,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘，威高血净报收于30.45元，上涨1.6%，换手率1.24%，成交量1.26万手，成交额3808.38万元。当日关注点交易信息汇总：10月9日主力资金净流入320.33万元，占总成交额8.41%。公司公告汇总：威高血净于2026年9月21日至30日赎回结构性存款25,500万元，获得收益30.59万元；截至公告日，闲置募集资金现金管理未到期余额为13,042万元，未超授权额度及期限。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200001193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","603014"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674688572","title":"【读财报】9月上市公司定增动态：募资总额超417亿元 威高血净、华虹公司募资额居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2674688572","media":"新华财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674688572?lang=zh_cn&edition=full","pubTime":"2026-10-09 07:18","pubTimestamp":1791501492,"startTime":"0","endTime":"0","summary":"新华财经北京10月9日电统计显示，2026年9月，A股上市公司共计实施定增21起，同比上升40%；实际募资总额约417.85亿元，同比下降71.13%。具体来看，威高血净、华虹公司、通富微电的发行规模相对居前。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610093890077592.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610093890077592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["603014"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673072353","title":"威高血净：关于使用暂时闲置募集资金进行现金管理到期赎回的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2673072353","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673072353?lang=zh_cn&edition=full","pubTime":"2026-10-08 20:02","pubTimestamp":1791460920,"startTime":"0","endTime":"0","summary":" 证券日报网讯 10月8日，威高血净发布公告称，2026年8月20日，公司使用暂时闲置募集资金向招商银行股份有限公司威海高新支行购买了金额为4,000万元人民币的结 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261008/c680491407.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261008/c680491407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["MMKT","BK0251","603014","IQMM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670409006","title":"股市必读：威高血净新发布《山东威高血液净化制品股份有限公司发行股份购买资产暨关联交易实施情况暨新增股份上市公告书（摘要）》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670409006","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670409006?lang=zh_cn&edition=full","pubTime":"2026-09-28 02:48","pubTimestamp":1790534892,"startTime":"0","endTime":"0","summary":"关于股东权益变动暨控股股东变更的提示性公告山东威高血液净化制品股份有限公司因发行股份购买资产，导致控股股东由威高集团变更为威高股份，实际控制人仍为陈学利；本次交易完成后，公司总股本增加，威高股份持股比例为51.66%，成为控股股东；相关信息披露义务人已按规定履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800001384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603014","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669549957","title":"威高血净（603014）披露发行股份购买资产暨关联交易实施情况暨新增股份上市公告书（摘要），9月24日股价下跌1.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669549957","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669549957?lang=zh_cn&edition=full","pubTime":"2026-09-24 22:23","pubTimestamp":1790259795,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘，威高血净报收于31.15元，较前一交易日下跌1.36%，最新总市值为130.13亿元。近日，山东威高血液净化制品股份有限公司披露《发行股份购买资产暨关联交易实施情况暨新增股份上市公告书（摘要）》。标的资产已过户至上市公司名下，本次交易构成重大资产重组及关联交易，不构成重组上市。交易对方作出业绩补偿承诺，相关股份锁定期为36个月。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400041298.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","603014"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669610314","title":"威高血净最新公告：控股股东变更为威高股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2669610314","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669610314?lang=zh_cn&edition=full","pubTime":"2026-09-24 18:20","pubTimestamp":1790245226,"startTime":"0","endTime":"0","summary":"威高血净(603014.SH)公告称，公司发行股份购买资产暨关联交易事项完成新增股份登记，威高股份直接持有公司51.66%股份，成为控股股东；实际控制人仍为陈学利。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400032134.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603014","LU0173614495.USD","BK1222","LU0287142896.SGD","01066","BK0251","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669828124","title":"股市必读：威高血净（603014）9月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2669828124","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669828124?lang=zh_cn&edition=full","pubTime":"2026-09-23 03:04","pubTimestamp":1790103854,"startTime":"0","endTime":"0","summary":"截至2026年9月22日收盘，威高血净报收于31.48元，上涨0.03%，换手率0.96%，成交量9779.0手，成交额3080.53万元。董秘最新回复投资者： 您好，请问，贵公司截止9月20日股东人数是多少？依据信息披露相关规则，公司在定期报告中统一披露股东人数。根据公司2026年半年度报告，截至2026年6月30日，公司普通股股东总数16,377人。当日关注点交易信息汇总：9月22日主力资金净流入75.77万元，占总成交额2.46%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300003178.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603014","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668994059","title":"股市必读：威高血净（603014）9月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2668994059","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668994059?lang=zh_cn&edition=full","pubTime":"2026-09-18 00:53","pubTimestamp":1789663990,"startTime":"0","endTime":"0","summary":"截至2026年9月17日收盘，威高血净报收于30.8元，上涨0.72%，换手率0.6%，成交量6119.0手，成交额1878.49万元。董秘最新回复投资者： 领导您好，公司现阶段已完成威高普瑞资产注入重组工作，威高普瑞的主营业务为预灌封给药系统及自动安全给药系统等医药包材的研发、生产与销售。公司一直秉持着以创新驱动发展的经营理念，密切关注AI等新技术在研发、生产领域的应用趋势。当日关注点交易信息汇总：9月17日主力资金净流入55.08万元，占总成交额2.93%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091800000455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603014","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668965469","title":"威高血净：公司密切关注AI等新技术在研发、生产领域的应用趋势","url":"https://stock-news.laohu8.com/highlight/detail?id=2668965469","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668965469?lang=zh_cn&edition=full","pubTime":"2026-09-17 18:06","pubTimestamp":1789639572,"startTime":"0","endTime":"0","summary":"请问公司在新产品研发和生产中是否有运用到AI，是否在引进或应用到AI协助研发和生产？公司一直秉持着以创新驱动发展的经营理念，密切关注AI等新技术在研发、生产领域的应用趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700030341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603014","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667250029","title":"每周股票复盘：威高血净（603014）并购威高普瑞获证监会通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2667250029","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667250029?lang=zh_cn&edition=full","pubTime":"2026-09-13 03:46","pubTimestamp":1789242371,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，威高血净报收于30.79元，较上周的31.34元下跌1.75%。本周，威高血净9月8日盘中最高价报31.9元。本周关注点来自机构调研要点：公司发行股份购买威高普瑞100%股权已获证监会批复通过。公司便携式CRRT预计在2026年取证，后续进行商业化销售。分派对象为截至股权登记日在中国证券登记结算有限责任公司上海分公司登记在册的全体股东。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300001395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","603014"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665317338","title":"威高血净：9月7日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2665317338","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665317338?lang=zh_cn&edition=full","pubTime":"2026-09-07 23:01","pubTimestamp":1788793265,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月7日威高血净发布公告称公司于2026年9月7日召开业绩说明会。威高血净2026年中报显示，上半年度公司主营收入17.58亿元，同比下降0.36%；归母净利润2.3亿元，同比上升4.32%；扣非净利润2.18亿元，同比上升1.59%；其中2026年第二季度，公司单季度主营收入8.54亿元，同比下降1.69%；单季度归母净利润1.11亿元，同比上升3.31%；单季度扣非净利润1.06亿元，同比上升1.1%；负债率14.63%，投资收益2699.52万元，财务费用673.88万元，毛利率37.88%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700033071.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","603014"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665736667","title":"每周股票复盘：威高血净（603014）获准发行股份收购威高普瑞","url":"https://stock-news.laohu8.com/highlight/detail?id=2665736667","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665736667?lang=zh_cn&edition=full","pubTime":"2026-09-06 03:40","pubTimestamp":1788637221,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，威高血净报收于31.34元，较上周的32.02元下跌2.12%。本周，威高血净9月1日盘中最高价报32.34元。本周关注点公司公告汇总：威高血净获证监会批复，发行股份购买威高普瑞100%股权获注册核准。公司公告汇总：威高普瑞业绩承诺期净利润分别不低于63,950.92万元、72,017.07万元和78,352.29万元。本次交易对价为851,081.38万元，以发行股份方式支付。交易完成后，上市公司控股股东将变更为威高股份，实际控制人仍为陈学利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600001273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","603014"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664865192","title":"股市必读：威高血净新发布《山东威高血液净化制品股份有限公司关于发行股份购买资产暨关联交易事项获得中国证券监督管理委员会同意注册的批复的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664865192","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664865192?lang=zh_cn&edition=full","pubTime":"2026-09-02 02:41","pubTimestamp":1788288069,"startTime":"0","endTime":"0","summary":"山东威高血液净化制品股份有限公司关于发行股份购买资产暨关联交易报告书修订说明的公告公司已收到中国证监会同意本次交易注册的批复，并对重组报告书封面、重大事项提示、重大风险提示、第一章及第十二章等内容进行修订，更新了报告书名称、决策程序、审批情况及风险因素等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200002513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603014","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664383037","title":"威高血净（603014）披露使用暂时闲置募集资金进行现金管理到期赎回的公告，9月1日股价上涨0.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664383037","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664383037?lang=zh_cn&edition=full","pubTime":"2026-09-01 17:37","pubTimestamp":1788255472,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘，威高血净报收于31.73元，较前一交易日上涨0.67%，最新总市值为132.55亿元。该股当日开盘31.88元，最高32.34元，最低31.63元，成交额达5202.41万元，换手率为1.61%。公告显示，公司近期赎回民生银行威海分行和威海银行股份有限公司东城支行的结构性存款产品，合计金额21,500万元，获得实际收益25.25万元。截至公告日，公司使用闲置募集资金进行现金管理未到期余额为11,042万元，未超出董事会授权额度和期限。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100031066.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603014","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664007132","title":"股市必读：威高血净新发布《山东威高血液净化制品股份有限公司关于发行股份购买资产暨关联交易事项获得中国证券监督管理委员会同意注册的批复的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664007132","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664007132?lang=zh_cn&edition=full","pubTime":"2026-09-01 01:27","pubTimestamp":1788197232,"startTime":"0","endTime":"0","summary":"山东威高血液净化制品股份有限公司发行股份购买资产暨关联交易报告书摘要本次交易构成关联交易和重大资产重组，不构成重组上市；交易价格为851,081.38万元，以发行股份方式支付；交易完成后，上市公司控股股东将变更为威高股份，实际控制人仍为陈学利。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100001955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603014","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663097070","title":"威高血净（603014）披露发行股份购买资产获证监会注册批复，8月31日股价下跌1.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663097070","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663097070?lang=zh_cn&edition=full","pubTime":"2026-08-31 22:17","pubTimestamp":1788185850,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，威高血净报收于31.52元，较前一交易日下跌1.56%，最新总市值为131.68亿元。该股当日开盘31.8元，最高31.85元，最低30.98元，成交额达5058.32万元，换手率为1.59%。近日，山东威高血液净化制品股份有限公司发布《关于发行股份购买资产暨关联交易事项获得中国证券监督管理委员会同意注册的批复的公告》。批复自下发之日起12个月内有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100037064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603014","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663010033","title":"每周股票复盘：威高血净（603014）Q2净利增3.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663010033","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663010033?lang=zh_cn&edition=full","pubTime":"2026-08-30 04:31","pubTimestamp":1788035469,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，威高血净报收于32.02元，较上周的32.49元下跌1.45%。本周，威高血净8月26日盘中最高价报32.58元。威高血净当前最新总市值133.76亿元，在医疗器械板块市值排名18/129，在两市A股市值排名1415/5211。本周关注点股本股东变化：截至2026年6月30日股东户数为1.64万户，较前期减少2.65%。业绩披露要点：2026年第二季度归母净利润1.11亿元，同比上升3.31%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001390.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603014","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662278723","title":"股市必读：威高血净新发布《山东威高血液净化制品股份有限公司2026年半年度报告摘要》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662278723","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662278723?lang=zh_cn&edition=full","pubTime":"2026-08-27 07:44","pubTimestamp":1787787857,"startTime":"0","endTime":"0","summary":"公司公告汇总山东威高血液净化制品股份有限公司2026年半年度报告摘要截至2026年6月30日，公司总资产8,469,578,654.12元，较上年度末下降1.61%；归属于上市公司股东的净资产7,230,623,917.94元，较上年度末增长1.57%。山东威高血液净化制品股份有限公司关于聘任证券事务代表的公告公司于2026年8月24日召开第二届董事会第二十五次会议，审议通过《关于聘任证券事务代表的议案》，同意聘任王浩为公司证券事务代表，任期自董事会审议通过之日起至本届董事会任期届满之日止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700014398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603014","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662736549","title":"图解威高血净中报：第二季度单季净利润同比增长3.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662736549","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662736549?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:49","pubTimestamp":1787654977,"startTime":"0","endTime":"0","summary":"证券之星消息，威高血净2026年中报显示，上半年度公司主营收入17.58亿元，同比下降0.36%；归母净利润2.3亿元，同比上升4.32%；扣非净利润2.18亿元，同比上升1.59%；其中2026年第二季度，公司单季度主营收入8.54亿元，同比下降1.69%；单季度归母净利润1.11亿元，同比上升3.31%；单季度扣非净利润1.06亿元，同比上升1.1%；负债率14.63%，投资收益2699.52万元，财务费用673.88万元，毛利率37.88%。财报数据概要请见下图:本文数据来源于威高血净2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500039827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603014"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662205574","title":"股市必读：威高血净（603014）8月24日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2662205574","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662205574?lang=zh_cn&edition=full","pubTime":"2026-08-25 03:20","pubTimestamp":1787599227,"startTime":"0","endTime":"0","summary":"截至2026年8月24日收盘，威高血净报收于31.94元，下跌1.69%，换手率1.04%，成交量1.05万手，成交额3362.96万元。董秘最新回复投资者： 您好，请问，贵公司截止8月20日股东人数是多少？依据信息披露相关规则，公司在定期报告中统一披露股东人数。根据公司2026年第一季度报告，截至2026年3月31日，公司普通股股东总数16,822人。当日关注点交易信息汇总：8月24日主力资金净流出138.75万元，占总成交额4.13%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500006343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603014","BK0251"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791904212819,"stockEarnings":[{"period":"1week","weight":-0.0279},{"period":"1month","weight":-0.0212},{"period":"3month","weight":-0.0865},{"period":"6month","weight":-0.192},{"period":"1year","weight":-0.2129},{"period":"ytd","weight":-0.2317}],"compareEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":-0.0234},{"period":"3month","weight":-0.0428},{"period":"6month","weight":-0.0571},{"period":"1year","weight":-0.0256},{"period":"ytd","weight":-0.0432}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东威高血液净化制品股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"16377人(较上一季度减少2.65%)","perCapita":"6196股","listingDate":"2025-05-19","address":"山东省威海市环翠区威海火炬高技术产业开发区威高西路7号","registeredCapital":"69479万元","survey":" 山东威高血液净化制品股份有限公司的主营业务是血液净化医用制品的研发、生产和销售。公司的主要产品是血液透析器、血液透析管路、血液透析机以及腹膜透析液。报告期内，公司收到中华人民共和国工业和信息化部下发的《制造业单项冠军企业证书》。","listedPrice":26.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"威高血净(603014)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供威高血净(603014)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"威高血净,603014,威高血净股票,威高血净股票老虎,威高血净股票老虎国际,威高血净行情,威高血净股票行情,威高血净股价,威高血净股市,威高血净股票价格,威高血净股票交易,威高血净股票购买,威高血净股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"威高血净(603014)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供威高血净(603014)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}